Federal health experts now anticipate that the majority of Americans will have access to a fourth COVID-19 booster vaccination in early September. This adjuvant vaccination is intended to enhance protection against the original SARS-CoV-2 strains, as well as the common Omicron subvariants BA.4 and BA.5. After receiving FDA clearance in early September, Pfizer’s booster might be on sale soon after. However, Moderna’s supplemental shot might be released at a later time.
Multiple news outlets have reported that federal health authorities have suggested that a fourth COVID-19 vaccination would be available to Americans soon after Labor Day. In an effort to slow the spread of the Omicron-fueled SARS-CoV-2 subvariant this coming autumn, Pfizer-BioNTech and Moderna have developed and are producing updated booster vaccinations. Those other than those over 65 or with impaired immune systems will be eligible to get this booster injection, expanding the pool of people who may benefit from it.
Health experts have been recommending doses called “bivalent” vaccinations that are designed to combat two viral Omicron subvariant strains, BA.4 and BA.5, that have been responsible for the vast majority of new breakthrough cases this summer. According to data recently released by the CDC, more than 90% of all instances of COVID-19 in the United States may be traced back to the BA.5.
New coronavirus booster vaccinations will also work to restore protection against the first strain of the virus that patients were exposed to during the pandemic. The Centers for Disease Control and Prevention (CDC) will have the last word on when new booster immunizations are made available to the public, and this decision is expected to be made in early September, just before the federal Labor Day vacation. NBC News reports that teams from Pfizer and Moderna are working to get preliminary FDA clearance; however, the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC) will have the ultimate say. The board is scheduled to convene on September 1 and 2, and a decision is anticipated soon afterwards.